TMCnet News
Supernus to Present at Three November Healthcare ConferencesROCKVILLE, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and Company update as well as host investor meetings, at the following three conferences: Stifel 2018 Healthcare Conference Jefferies 2018 London Healthcare Conference Piper Jaffray 30th Annual Healthcare Conference Investors interested in arranging a meeting with the Company's management during these conferences should contact the rspective conference coordinators. A live webcast of the respective presentations can be accessed by visiting ‘Events & Presentations’ in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the respective conferences on the Company's website. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and Oxtellar XR for the treatment of bipolar disorder. CONTACT: Jack A. Khattar, President and CEO Or Investor Contact: |